TY - JOUR
T1 - Antibody therapy of pediatric B-cell lymphoma
AU - Meyer-Wentrup, Friederike
AU - de Zwart, Verena
AU - Bierings, Marc
PY - 2013
Y1 - 2013
N2 - B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease. Therapeutic toxicity remains high calling for better targeted and thus less toxic therapies. Therapeutic antibodies have become a standard element of B-cell lymphoma therapy in adults. Clinical experience in pediatric lymphoma patients is still very limited. This review outlines the rationale for antibody treatment of B-cell lymphomas in children and describes potential target structures on B-cell lymphoma cells. It summarizes the clinical experience of antibody therapy of B-cell lymphoma in children and gives an outlook on new developments and challenges for antibody therapy of pediatric B-cell lymphoma.
AB - B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease. Therapeutic toxicity remains high calling for better targeted and thus less toxic therapies. Therapeutic antibodies have become a standard element of B-cell lymphoma therapy in adults. Clinical experience in pediatric lymphoma patients is still very limited. This review outlines the rationale for antibody treatment of B-cell lymphomas in children and describes potential target structures on B-cell lymphoma cells. It summarizes the clinical experience of antibody therapy of B-cell lymphoma in children and gives an outlook on new developments and challenges for antibody therapy of pediatric B-cell lymphoma.
KW - Cancer immunotherapy
KW - Cancer therapeutics
KW - Individualized medicine
KW - Pediatric B-cell lymphoma
KW - Therapeutic antibodies
UR - http://www.scopus.com/inward/record.url?scp=84890724300&partnerID=8YFLogxK
U2 - 10.3389/fonc.2013.00068
DO - 10.3389/fonc.2013.00068
M3 - Short survey
AN - SCOPUS:84890724300
SN - 2234-943X
VL - 3 APR
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - Article 00068
ER -